Literature DB >> 22453091

IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Johan Nilvebrant1, D Cameron Dunlop2, Aroop Sircar3, Thierry Wurch4, Emilia Falkowska2, Janice M Reichert5, Gustavo Helguera6, Emily C Piccione7, Simon Brack8, Sven Berger9.   

Abstract

The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5-8, 2011 in San Diego, CA. The meeting drew ~800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics session comprised five sessions: (1)Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage antibody therapeutics and (5) antibody drug conjugates and bispecific antibodies.

Entities:  

Keywords:  antibody engineering; antibody therapeutics; antibody-antigen structure; antibody-drug conjugates; bispecific antibodies; computational design; vaccine design

Mesh:

Substances:

Year:  2012        PMID: 22453091      PMCID: PMC3361653          DOI: 10.4161/mabs.4.2.19495

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  106 in total

1.  Selection for improved subtiligases by phage display.

Authors:  S Atwell; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 3.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

4.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Authors:  William J Wolfgang; Todd W Miller; Jack M Webster; James S Huston; Leslie M Thompson; J Lawrence Marsh; Anne Messer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

5.  CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Authors:  Kam Fai Tse; Michael Jeffers; Vincent A Pollack; Denise A McCabe; Melanie L Shadish; Nikolai V Khramtsov; Craig S Hackett; Suresh G Shenoy; Bing Kuang; Ferenc L Boldog; John R MacDougall; Luca Rastelli; John Herrmann; Michael Gallo; Gadi Gazit-Bornstein; Peter D Senter; Damon L Meyer; Henri S Lichenstein; William J LaRochelle
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

6.  The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.

Authors:  Peter F Wright; Ruth A Karron; Robert B Belshe; Jian R Shi; Valerie B Randolph; Peter L Collins; Alice F O'Shea; William C Gruber; Brian R Murphy
Journal:  Vaccine       Date:  2007-08-28       Impact factor: 3.641

7.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

Review 8.  Engineering T cells for cancer therapy.

Authors:  W Mansoor; D E Gilham; F C Thistlethwaite; R E Hawkins
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

Review 9.  Drug Insight: emerging therapies for amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Clin Pract Nephrol       Date:  2006-05

10.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Authors:  Troy Querec; Soumaya Bennouna; Sefik Alkan; Yasmina Laouar; Keith Gorden; Richard Flavell; Shizuo Akira; Rafi Ahmed; Bali Pulendran
Journal:  J Exp Med       Date:  2006-02-06       Impact factor: 14.307

View more
  3 in total

1.  Mabs's communication networks.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).

Authors:  Mirian Mendoza; Angela Ballesteros; Qi Qiu; Luis Pow Sang; Soumya Shashikumar; Sofia Casares; Teodor-D Brumeanu
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

3.  PyIgClassify: a database of antibody CDR structural classifications.

Authors:  Jared Adolf-Bryfogle; Qifang Xu; Benjamin North; Andreas Lehmann; Roland L Dunbrack
Journal:  Nucleic Acids Res       Date:  2014-11-11       Impact factor: 19.160

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.